The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE in Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
November 05, 2014 at 06:36 AM EST
The Medicines Company (NASDAQ: MDCO) today announced enrollment of the first patient in its Phase 3 clinical trial program for ...
